MedTrace Logo

Agomelatine in Depressed Patients With Fibromyalgia

NCT01731899 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2014-05-07

No results posted yet for this study

Summary

Depression and unrefreshed sleep are frequent in patients with fibromyalgia. Agomelatine is a new antidepressant with sleep-promoting properties. The objective of this study include the assessment of agomelatine therapy in patients with depression and fibromyalgia both on the severity of depressive symptomatology and sleep quality.

Conditions

Interventions

DRUG

agomelatine

Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration

Sponsors & Collaborators

  • Universidad de Granada

    lead OTHER

Principal Investigators

  • Elena P Calandre, MD · Universidad de Granada

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-10-31
Completion
2012-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01731899 on ClinicalTrials.gov